NCT06346392 2026-03-09
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
Clinical Trials
102 trialsNCT06219941 2026-02-12
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
AstraZeneca
Phase 2 Recruiting
NCT04640480 2026-01-27
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
SN BioScience
Phase 1 Completed
NCT07364422 2026-01-23
To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer
Onconic Therapeutics Inc.
Phase 1/2 Not yet recruiting
NCT04342910 2026-01-20
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT06974110 2026-01-16
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
Phase 1 Recruiting
NCT04329494 2025-12-10
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT03872947 2025-08-03
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries, Inc
Phase 1 Active not recruiting
NCT02611024 2025-07-09
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
Phase 1/2 Completed
NCT06769425 2025-06-24
HS-10502
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT02366819 2025-06-13
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
University of Chicago
Phase 4 Recruiting
NCT04581473 2025-06-05
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
CARsgen Therapeutics Co., Ltd.
Phase 1/2 Active not recruiting
NCT05379790 2025-04-01
Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin
Erasmus Medical Center
Phase 1 Completed
NCT05319639 2025-02-27
Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
Fujian Cancer Hospital
Phase 1/2 Recruiting
NCT02485834 2025-01-20
FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT03368963 2025-01-07
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
Emory University
Phase 1/2 Active not recruiting
NCT04535401 2024-10-10
Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT01941316 2024-05-09
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Cancer Research and Biostatistics Clinical Trials Consortium
Phase 1/2 Completed
NCT04770623 2024-01-30
Docetaxel and Irinotecan in Gastric Cancer
Menoufia University
Phase 2 Completed
NCT06196554 2024-01-09
Gastric Cancer Organoids in the Screening of Neoadjuvant Drugs
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Unknown
NCT06197438 2024-01-09
Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT04714190 2023-12-21
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
RemeGen Co., Ltd.
Phase 3 Unknown
NCT05427383 2023-12-19
KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
Shanghai JMT-Bio Inc.
Phase 2/3 Recruiting
NCT00033657 2023-06-28
Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02333188 2023-05-31
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
University of Chicago
Phase 1 Completed
NCT05750290 2023-03-01
CKD-702 Plus Irinotecan in Gastric Cancer
National Cancer Center, Korea
Phase 2 Unknown
NCT05025033 2023-01-18
Chemotherapy Combined With Apatinib and PD-1 Antibody
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Completed
NCT05643677 2022-12-09
Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer
Fujian Medical University
Phase 2 Unknown
NCT00911820 2022-11-08
Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT04358354 2021-07-19
Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3 Unknown
NCT04934618 2021-06-22
A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT04915807 2021-06-07
Real-world Data (RWD) of Ramucirumab Plus Paclitaxel
Hallym University Medical Center
Unknown
NCT04393584 2021-04-13
RusGCG-01
Blokhin's Russian Cancer Research Center
Phase 2/3 Unknown
NCT04442984 2021-04-13
IRIGA
Blokhin's Russian Cancer Research Center
Phase 2 Unknown
NCT00061932 2021-02-02
Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach
National Cancer Institute (NCI)
Phase 2 Completed
NCT04486651 2021-01-28
HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
Taizhou Hanzhong biomedical co. LTD
Phase 3 Unknown
NCT01084330 2020-12-10
Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer
Novartis
Phase 2 Completed
NCT00952003 2020-11-30
Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Completed
NCT02625623 2020-11-24
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
EMD Serono
Phase 3 Completed
NCT01928290 2020-08-25
FOLFIRINOX
Washington University School of Medicine
Phase 2 Completed
NCT04358341 2020-08-24
Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Unknown
NCT00003748 2020-08-03
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00020761 2020-08-03
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT01643499 2020-05-08
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
University of Chicago
Phase 1 Completed
NCT01498289 2019-11-07
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT01040312 2019-05-23
An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors
Daiichi Sankyo
Completed
NCT01271582 2019-01-29
Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients
Asan Medical Center
Phase 4 Unknown
NCT03668418 2018-09-12
xenoZ
University of Pisa
Unknown
NCT00003867 2018-09-10
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
Montefiore Medical Center
Phase 1 Completed
NCT00816777 2018-09-07
PARAGON
Generic Devices Consulting, Inc.
Phase 1/2 Terminated